Abbott Just Showed Its Growth Engine Has More Than One Cylinder

The healthcare giant’s stock jump was about more than an earnings beat, offering proof of a growth story broader and more resilient than you thought.

You could be forgiven for feeling a little nervous about Abbott Laboratories (ABT) heading into Thursday. The stock had been slipping, and whispers of a slowdown in hospital procedures were getting louder across the healthcare sector. Then the market opened, and Abbott surged +10.7% while the S&P 500 sagged.

So what changed overnight? The company delivered more than a simple earnings beat; it provided a direct answer to the market’s biggest anxieties.

How Did Abbott Defy The Gloom?

On the surface, the news was straightforward: Abbott posted adjusted earnings of $1.31 per share, clearing expectations of $1.28. More importantly, the company nudged its full-year profit forecast higher, now expecting between $5.45 and $5.60 per share. That confidence comes from seeing its overall sales growth accelerate to 4.8%, a faster clip than in the prior two quarters. But the real story is where that confidence is coming from, and it’s not the place everyone has been watching.

If Not Libre, Then What’s Driving The Bus?

For years, the main character in Abbott’s growth story has been its Diabetes Care division, with continuous glucose monitoring sales recently topping $2 billion in a single quarter. But that engine has cooled, with growth slowing to 9.5%. Management even acknowledged the business is on a “plateau” until the next major reimbursement expansion kicks in.

Instead of a problem, this turned out to be an opportunity for the rest of the portfolio to shine. The company made it clear that the acceleration it forecasts for the rest of the year will be driven by other divisions stepping up. Take Diagnostics, where the business that sells testing instruments and reagents to hospitals grew a powerful 13% this quarter. Or look to the Medical Devices segment, where the electrophysiology unit is gaining traction with new products, including a recently introduced catheter. This diversified healthcare company showed it isn’t a one-trick pony.

What About That Feared Healthcare Slowdown?

This is where Abbott turned its unique business model into a weapon. While investors worried about fewer patient procedures, Abbott pointed to its own real-time data. The company’s diagnostic instruments, spread across the U.S. and the globe, act as a barometer for healthcare activity. And according to the CEO, that data “continues to reflect strong and stable demand for testing.” It was a clear, data-backed rebuttal to one of the market’s biggest fears.

Abbott just proved its diversification is more than a talking point. But now that its other divisions have taken the lead, can they maintain that pace long enough for the next big catalyst in diabetes care to finally arrive?

Is The Momentum Built To Last?

Knowing why a stock ran is one thing; knowing whether the run has legs is another. The most durable moves are the ones a rising forecast is actually backing, rather than a good week of sentiment. Our Guidance Momentum screen tracks the S&P 500 names where a raised outlook meets real price momentum, so you can judge which runs are built to last.

Enjoy The Move, Then Check What It Did To Your Allocation

A move like this is even better to own than to watch, and it is also how one holding grows into an outsized share of a portfolio. How much damage any single position could do to your net worth is a question with a precise answer. The Trefis Wealth team computes it for investors professionally, with the same rules-based systematic discipline that runs our High Quality Portfolio. Request a free vulnerability audit of your biggest positions.